ARMODAFINIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H15NO2S
Molecular Weight	273.35
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C[S@@+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=YFGHCGITMMYXAQ-LJQANCHMSA-N

InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H15NO2S
Molecular Weight	273.35
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169http://www.drugbank.ca/drugs/DB00745
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Modafinil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. Modafinil is indicated for the improvement of wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8228	51.79 µM [IC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8228	51.79 µM [IC50]
Dopamine transporter 179 Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00745	Inhibitor 8228	13.0 µM [Ki]
Dopamine transporter 179 Target ID: CHEMBL238 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf	Inhibitor 8228	4.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Narcolepsy 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8360	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 9.1437118E11
Obstructive sleep apnea 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8360	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 9.1437118E11
Sleep disorder 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169	Primary	Approved 8360	NUVIGIL Approved Use NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. Launch Date 1.18186561E12

C_max

Value	Dose	Analyte	Population
7.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
4.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
105.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
136.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
150.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
189.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
142.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
146 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
75.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	Disc. AE: Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 6 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Disc. AE: Adverse event... AEs leading to discontinuation/dose reduction: Adverse event Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	Disc. AE: Rash, Angioneurotic edema... AEs leading to discontinuation/dose reduction: Rash (2%) Angioneurotic edema (1%) Hyperhidrosis (1%) Rash papular (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

AEs

AE	Significance	Dose	Population
Stevens-Johnson syndrome	1 patient Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
Adverse event	Disc. AE	400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
Headache	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
Angioneurotic edema	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Hyperhidrosis	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash papular	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash	2% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:77590	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:77590
ZINC	ZINC000003831139	http://zinc15.docking.org/substances/ZINC000003831139

PubMed

Title	Date	PubMed

Benefits and risks of pharmacotherapy for narcolepsy.	2002	12222990
Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil.	2002	11990384
Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.	2002 Apr	11936571
Effects of modafinil on heat thermoregulatory responses in humans at rest.	2002 Aug	12269790
Drugs under investigation for attention-deficit hyperactivity disorder.	2002 Aug	12211416
Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.	2002 Aug	12195441
Discriminative-stimulus effects of modafinil in cocaine-trained humans.	2002 Aug 1	12127202
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.	2002 Dec	12489899
Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity.	2002 Dec 15	12373742
Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy.	2002 Dec 24	12499477
Psychopharmacology of wakefulness: pathways and neurotransmitters.	2002 Jul	12143908
Gateways to clinical trials.	2002 Jul-Aug	12224444
Modafinil in the treatment of depression with severe comorbid medical illness.	2002 Jul-Aug	12189262
Attention deficit disorder in adults.	2002 Jun	12238735
Gateways to Clinical Trials. June 2002.	2002 Jun	12168506
Study of the addictive potential of modafinil in naive and cocaine-experienced rats.	2002 Jun	12073166
Secondary narcolepsy in children with brain tumors.	2002 Jun 15	12071545
The central nucleus of the amygdala and the wake-promoting effects of modafinil.	2002 Jun 21	12031546
Use of modafinil in spastic cerebral palsy.	2002 Mar	12026230
Acute behavioral and physiological effects of modafinil in drug abusers.	2002 Mar	11981223
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil.	2002 Mar-Apr	11981239
Modafinil monotherapy in depression.	2002 May	12052578
Effect of modafinil on core temperature during sustained wakefulness and exercise in a warm environment.	2002 Nov	12433231
Modafinil for social phobia and amphetamine dependence.	2002 Nov	12411237
Circadian rhythm of rectal temperature during sleep deprivation with modafinil.	2002 Oct	12398260
Adjunctive modafinil in ALS.	2002 Spring	11983803
Clinical applications of modafinil in stimulant abusers: low abuse potential.	2002 Summer	12202017
Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.	2003	14568034
Narcolepsy in the older adult: epidemiology, diagnosis and management.	2003	12696996
Fatigue in multiple sclerosis: definition, pathophysiology and treatment.	2003	12665396
[Therapy of day time fatigue in patients with multiple sclerosis].	2003	12658965
Three case reports of modafinil use in treating sedation induced by antipsychotic medications.	2003 Apr	12716260
Non-stimulant treatment of attention-deficit/hyperactivity disorder.	2003 Apr	12679740
Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.	2003 Apr	12657914
An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.	2003 Apr	12640225
[Modafinil: pharmacology and therapeutic perspectives].	2003 Jan	12618664
Cognitive enhancing effects of modafinil in healthy volunteers.	2003 Jan	12417966
Con: modafinil has no role in management of sleep apnea.	2003 Jan 15	12524248
Pro: modafinil has a role in management of sleep apnea.	2003 Jan 15	12524247
Modafinil treatment of opioid-induced sedation.	2003 Jun	12873263
Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.	2003 Jun	12798791
Modafinil--medical considerations for use in sustained operations.	2003 Jun	12793539
Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.	2003 Jun	12791341
Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.	2003 Jun	12709775
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.	2003 Mar	12621632
Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.	2003 Mar	12552359
Modafinil maintains waking in the fruit fly drosophila melanogaster.	2003 Mar 15	12683471
Modafinil increases histamine release in the anterior hypothalamus of rats.	2003 Mar 20	12614915
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.	2003 May 1	12681523

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of NUVIGIL (armodafinil) for each indication is as follows: obstructive sleep apnea or Narcolepsy: 150 mg to 250 mg once a day in the morning. Shift work disorder: 150 mg once a day, taken approximately one hour prior to start of the work shift.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:04:10 UTC 2023` Edited by `admin` on `Wed Jul 05 23:04:10 UTC 2023`
Record UNII	V63XWA605I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ARMODAFINIL

Official Name

English

ACETAMIDE, 2-((R)-(DIPHENYLMETHYL)SULFINYL)-

Systematic Name

English

CEP-10953

Code

English

ARMODAFINIL [WHO-DD]

Common Name

English

NSC-751850

Code

English

CEP-10952

Code

English

CRL-40982

Code

English

NUVIGIL

Brand Name

English

ARMODAFINIL [USP-RS]

Common Name

English

MODAFINIL, (R)-

Common Name

English

(-)-2-((R)-(DIPHENYLMETHYL)SULFINYL)ACETAMIDE

Systematic Name

English

NSC-758711

Code

English

ARMODAFINIL [MART.]

Common Name

English

2-[(R)-(Diphenylmethyl)sulfinyl]acetamide

Systematic Name

English

R-(-)-MODAFINIL

Common Name

English

armodafinil [INN]

Common Name

English

ARMODAFINIL [ORANGE BOOK]

Common Name

English

ARMODAFINIL [USAN]

Common Name

English

ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-, (-)-

Systematic Name

English

ARMODAFINIL [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N06BA13